Pasithea Common Stock Shares Outstanding from 2010 to 2025

KTTAW Stock  USD 0.02  0  10.48%   
Pasithea Therapeutics Common Stock Shares Outstanding yearly trend continues to be fairly stable with very little volatility. Common Stock Shares Outstanding will likely drop to about 1.2 M in 2025. Common Stock Shares Outstanding is the total number of shares of a company's common stock that are currently owned by all its shareholders. View All Fundamentals
 
Common Stock Shares Outstanding  
First Reported
2010-12-31
Previous Quarter
1.4 M
Current Value
1.2 M
Quarterly Volatility
272.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.44. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Latest Pasithea Therapeutics' Common Stock Shares Outstanding Growth Pattern

Below is the plot of the Common Stock Shares Outstanding of Pasithea Therapeutics Corp over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Pasithea Therapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Shares Outstanding10 Years Trend
Slightly volatile
   Common Stock Shares Outstanding   
       Timeline  

Pasithea Common Stock Shares Outstanding Regression Statistics

Arithmetic Mean863,645
Geometric Mean828,851
Coefficient Of Variation31.56
Mean Deviation240,250
Median688,918
Standard Deviation272,592
Sample Variance74.3B
Range721.7K
R-Value0.80
Mean Square Error28.5B
R-Squared0.64
Significance0.0002
Slope45,894
Total Sum of Squares1.1T

Pasithea Common Stock Shares Outstanding History

20251.2 M
20241.4 M
20231.2 M
20221.3 M
20211.2 M

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Shares Outstanding1.4 M1.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.